当前位置: 首页 > 医疗版 > 疾病专题 > 皮肤科 > 红斑荨麻疹类疾病 > 荨麻疹
编号:13522853
枸地氯雷他定+非索非那定治疗难治性荨麻疹患者的临床观察
http://www.100md.com 2020年1月1日 《健康大视野》 20201
     【摘 要】目的:分析枸地氯雷他定+非索非那定治疗难治性荨麻疹的疗效。方法:在我院收治的难治性荨麻疹患者中选取58例,起止时间是2017年3月~2019年6月。分为2个小组:对照组29例,单独使用枸地氯雷他定;试验组29例,联合应用非索非那定。评定临床疗效。结果:试验组总有效28例(96.6%),高于对照组的22例(75.9%);治疗后,试验组CD3+、CD4+、CD4+/CD8+指标更高(P<0.05)。结论:枸地氯雷他定+非索非那定治疗难治性荨麻疹疗效确切,有利于提高患者的免疫能力,值得推广。

    【关键词】难治性荨麻疹;枸地氯雷他定;非索非那定;免疫指标

    Abstract:Objective To analyze the efficacy of loratadine citrate plus fexofenadine in the treatment of refractory urticaria. Methods: 58 patients with refractory urticaria were selected from March 2017 to June 2019. They were divided into two groups: the control group (29 cases) treated with loratadine citrate alone and the experimental group (29 cases) treated with fexofenadine in combination. To evaluate the clinical efficacy. Results: 28 cases (96.6%) were effective in the experimental group ......

您现在查看是摘要页,全文长 3935 字符